Process areas for improvement ID'd in early prostate cancer

August 22, 2012
Process areas for improvement ID'd in early prostate cancer
For men with early prostate cancer undergoing expectant management, compliance with RAND structural indicators is high, but there is considerable variability in compliance with process indicators, according to a study published in the September issue of The Journal of Urology.

(HealthDay) -- For men with early prostate cancer undergoing expectant management, compliance with RAND structural indicators is high, but there is considerable variability in compliance with process indicators, according to a study published in the September issue of The Journal of Urology.

Jamie Ritchey, M.P.H., from the American College of Surgeons in Chicago, and colleagues abstracted medical records data and measured compliance with the RAND-developed quality indicators (structure and process). Data were reviewed for 13,876 men with early-stage prostate cancer undergoing expectant management in 2000 to 2001.

The researchers found that there was high compliance with structural indicators (greater than 80 percent), while compliance with process indicators varied (19 to 87 percent). Differences in process indicators were seen for models based on hospital type and , but not for age, race, or .

"Using the RAND quality indicators, this study revealed several process areas for quality improvement among men with early-stage prostate cancer on expectant management in the United States," the authors write. "Efforts to improve the quality of early-stage care need to move beyond the paradigm of age, race, and insurance status."

One author disclosed financial ties to diagnostics manufacturers.

Explore further: Excess body weight associated with increased risk for prostate cancer recurrence

More information: Abstract
Full Text
Editorial (subscription or payment may be required)

Related Stories

Excess body weight associated with increased risk for prostate cancer recurrence

April 3, 2012
Researchers have found an association between excess body weight and an increased risk for cancer recurrence in men with clinically localized prostate cancer.

Relief of urinary symptoms is an underappreciated benefit of early stage prostate cancer treatment

May 20, 2012
Treatment of early stage prostate cancer can also result in improved quality of life for a subgroup of men who suffer from lower urinary tract symptoms (LUTS), according to an abstract of a Beth Israel Deaconess Medical Center-led ...

Recommended for you

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.